Fresenius SE EBITDA 2016-2024 | FSNUY

Fresenius SE EBITDA for the quarter ending June 30, 2024 was $0.629B, a 54.18% decline year-over-year.

  • Fresenius SE 2023 EBITDA was 2.837B, a 57.22% decline from 2022.
  • Fresenius SE 2022 EBITDA was 6.631B, a 17.87% decline from 2021.
  • Fresenius SE 2021 EBITDA was 8.075B, a 0.44% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.

Fresenius SE EBITDA 2016-2024 | FSNUY

  • Fresenius SE 2023 EBITDA was 2.837B, a 57.22% decline from 2022.
  • Fresenius SE 2022 EBITDA was 6.631B, a 17.87% decline from 2021.
  • Fresenius SE 2021 EBITDA was 8.075B, a 0.44% decline from 2020.

EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company NameMarket
Cap
Quest Diagnostics (DGX)$18.3B
DaVita (DVA)$13.6B
Encompass Health (EHC)$10.2B
Chemed (CHE)$8.6B
Elanco Animal Health (ELAN)$6.6B
RadNet (RDNT)$6.1B
Option Care Health (OPCH)$3.9B
Amedisys (AMED)$3B
LifeStance Health (LFST)$2.8B
Astrana Health (ASTH)$2.4B
Addus HomeCare (ADUS)$2.3B
U.S Physical Therapy (USPH)$1.5B
Aveanna Healthcare Holdings (AVAH)$1.1B
Pennant (PNTG)$1.1B
Atai Life Sciences (ATAI)$270M
Daxor (DXR)$45M
Psychemedics (PMD)$14M
MEDIROM Healthcare Technologies (MRM)$14M
ATI Physical Therapy (ATIP)$8M
Ontrak (OTRK)$8M
IMAC Holdings (BACK)$1M